Our Pricing

Understanding Mounjaro Wegovy Dose Equivalent for Safe Switching

Finding the correct mounjaro wegovy dose equivalent is essential for patients considering switching between these GLP-1 receptor agonist treatments. While both Mounjaro (tirzepatide) and Wegovy (semaglutide) are licensed for weight management in the UK, they work through different mechanisms and cannot be converted on a simple milligram-for-milligram basis. This guide explains the clinical approach to transitioning between treatments, helping you make an informed decision with your prescriber.

How Mounjaro Wegovy Dose Equivalent Works Clinically

Understanding the mounjaro wegovy dose equivalent requires recognising that these medications have fundamentally different pharmacological profiles. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist, whilst Wegovy contains semaglutide, a selective GLP-1 receptor agonist [1]. There is no direct milligram-to-milligram conversion between the two medications because they act on different receptor systems with varying potencies.

Clinical guidance from the MHRA indicates that when switching between GLP-1 treatments, prescribers typically restart at the manufacturer's recommended initial dose for the new medication [2]. For Wegovy, this means beginning at 0.25mg weekly and following the standard dose escalation schedule. For Mounjaro, patients start at 2.5mg weekly with gradual increases every four weeks. This approach minimises gastrointestinal side effects and allows your body to adjust to the new medication's profile.

The decision to switch between Mounjaro and Wegovy often comes down to individual response, tolerability, and cost considerations. At Cured Pharmacy, Mounjaro is available from £124.99 subject to prescriber approval, whilst Wegovy starts from £124.99, making cost comparison an important factor in your treatment choice. Both medications require completion of a clinical assessment by our UK-registered prescribers before dispensing.

Mounjaro Wegovy Dose Equivalent: Clinical Trial Data Comparison

When evaluating mounjaro wegovy dose equivalent options, clinical trial outcomes provide valuable context. The STEP trials for semaglutide demonstrated average weight loss of 15-17% of body weight at the 2.4mg maintenance dose over 68 weeks [3]. Meanwhile, the SURPASS trials for tirzepatide showed average weight reductions of 15-22% depending on the maintenance dose (10mg or 15mg) over similar timeframes [4].

These trial results suggest that whilst both medications are highly effective, tirzepatide at higher doses may offer slightly superior weight loss outcomes for some patients. However, individual responses vary considerably, and factors such as adherence, lifestyle modifications, and baseline metabolic health significantly influence results. Your prescriber will consider your treatment history, previous response to GLP-1 medications, and current health status when recommending a switch.

Pharmacokinetic Differences Affecting Dose Equivalence

The mounjaro wegovy dose equivalent question is complicated by different half-lives and dosing frequencies. Both medications are administered once weekly, but semaglutide has a half-life of approximately 7 days, whilst tirzepatide's half-life is around 5 days [1]. This pharmacokinetic difference means the medications accumulate and clear from your system at different rates, influencing how switching should be managed clinically.

When transitioning from Wegovy to Mounjaro, prescribers typically recommend waiting until your next scheduled Wegovy dose would have been due, then starting Mounjaro at the initial 2.5mg dose. The reverse transition follows similar timing principles. This approach prevents overlapping GLP-1 receptor stimulation whilst avoiding gaps in treatment that might trigger rebound appetite or blood glucose fluctuations.

Switching Between Mounjaro and Wegovy: Practical Dose Equivalent Guidance

For patients seeking mounjaro wegovy dose equivalent switching protocols, the standard clinical approach prioritises safety over attempting direct dose matching. If you're currently stable on Wegovy 2.4mg weekly and considering switching to Mounjaro, your prescriber will likely recommend starting at Mounjaro 2.5mg weekly, then escalating according to the licensed schedule: 5mg, 7.5mg, 10mg, 12.5mg, and potentially 15mg at four-week intervals [2].

Conversely, switching from Mounjaro to Wegovy follows the Wegovy escalation schedule starting at 0.25mg weekly, regardless of your current Mounjaro dose. This graduated approach, whilst requiring patience through the titration period, significantly reduces the risk of severe nausea, vomiting, and other gastrointestinal adverse effects that can occur with GLP-1 receptor agonists.

Some patients ask whether they can start the new medication at a higher dose to match their perceived level of treatment intensity. This is not recommended and falls outside UK prescribing guidelines. The dose escalation schedules exist to optimise tolerability and safety, and attempting to bypass these steps increases the likelihood of discontinuation due to side effects.

Monitoring During Mounjaro Wegovy Dose Equivalent Transitions

When switching between treatments using mounjaro wegovy dose equivalent principles, regular monitoring becomes essential. Your prescriber may recommend checking weight, blood pressure, and potentially HbA1c levels (if you have type 2 diabetes) at baseline and during the transition period. This data helps assess whether the new medication is providing comparable or superior metabolic benefits.

Gastrointestinal symptoms should be tracked carefully during the first 8-12 weeks of the new medication. Mild nausea is common with both treatments but typically improves as your body adjusts. Persistent or severe symptoms warrant contacting your prescriber, as dose adjustments or additional supportive measures may be needed. At Cured Pharmacy, our clinical team remains available to support you throughout treatment transitions, ensuring optimal outcomes and safety.

Cost Considerations in Mounjaro Wegovy Dose Equivalent Decisions

Beyond clinical mounjaro wegovy dose equivalent factors, cost plays a significant role in treatment selection for UK patients. Wegovy is currently priced from £124.99 at Cured Pharmacy, whilst Mounjaro starts from £124.99, representing a notable price difference over long-term treatment [5]. New patients can Save £20 off their first order using code Weightlossnew, making initial treatment more accessible.

When comparing annual treatment costs, Wegovy at maintenance dosing represents a more economical option for many patients, potentially saving hundreds of pounds yearly compared to Mounjaro. However, if clinical trials suggest you might achieve superior weight loss outcomes with tirzepatide, the additional cost may be justified by better health results and reduced obesity-related comorbidity risks.

It's worth noting that both medications require ongoing prescription and cannot be purchased without clinical assessment. The total cost of treatment includes not just the medication price but also consultation fees, though at Cured Pharmacy our online clinical assessments are completed free of charge in under three minutes. This transparent pricing model ensures you understand the full financial commitment before starting treatment.

Side Effect Profiles and Mounjaro Wegovy Dose Equivalent Tolerability

When considering mounjaro wegovy dose equivalent switching, understanding comparative side effect profiles helps set realistic expectations. Both medications share common GLP-1-related adverse effects including nausea, diarrhoea, constipation, and reduced appetite [3][4]. However, tirzepatide's dual receptor mechanism may produce slightly different tolerability patterns in some patients.

Clinical trial data indicates that gastrointestinal side effects occur in approximately 40-50% of patients with both medications, though most cases are mild to moderate and resolve within weeks [1]. Serious adverse effects such as pancreatitis or gallbladder disease remain rare but require immediate medical attention. Your prescriber will review your medical history for contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Some patients switch from Wegovy to Mounjaro (or vice versa) specifically due to tolerability issues with their initial treatment. If you experienced persistent nausea on semaglutide, tirzepatide's different receptor profile might be better tolerated, though this varies individually. Conversely, patients struggling with Mounjaro side effects may find semaglutide more suitable. These decisions should always be made in consultation with your prescriber rather than through self-directed switching.

Managing Side Effects During Dose Equivalent Transitions

Successfully navigating mounjaro wegovy dose equivalent transitions involves proactive side effect management. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce gastrointestinal symptoms during the titration phase. Some patients find that administering the injection on the same day each week but at a different time of day helps minimise nausea interference with daily activities.

If side effects become intolerable during the escalation schedule, your prescriber may recommend extending the time at your current dose before increasing further. This flexible approach, whilst prolonging the time to reach maintenance dosing, often improves long-term adherence and treatment success. Never adjust your dose without prescriber guidance, as both under-dosing and over-dosing can compromise treatment efficacy and safety.

Making Your Mounjaro Wegovy Dose Equivalent Decision with Cured Pharmacy

Choosing between Mounjaro and Wegovy using mounjaro wegovy dose equivalent considerations ultimately requires balancing clinical effectiveness, tolerability, cost, and personal preferences. At Cured Pharmacy, our UK-registered clinical team (led by Superintendent Pharmacist Tarun Kumar, GPhC 2233073) provides personalised guidance through our free online consultation service, helping you select the most appropriate treatment for your individual circumstances.

The consultation process takes under three minutes and covers your medical history, current medications, weight loss goals, and any previous experience with GLP-1 treatments. Based on this assessment, our prescribers determine whether Mounjaro, Wegovy, or alternative weight management treatments are suitable and safe for you. All medications dispensed are genuine UK-licensed products, ensuring quality and regulatory compliance.

If approved, your medication is dispensed from our GPhC-registered pharmacy (9012511) with discreet packaging and next-day delivery options available. We provide ongoing clinical support throughout your treatment journey, including guidance on dose escalation, side effect management, and switching between treatments if your initial choice proves suboptimal. With transparent pricing and the lowest prices guaranteed in the UK, Cured Pharmacy makes effective weight management treatment accessible and affordable.

To begin your assessment for either Mounjaro or Wegovy, complete our online consultation today. Whether you're new to GLP-1 treatments or considering switching from your current medication, our clinical team will guide you through the mounjaro wegovy dose equivalent decision-making process, ensuring you receive safe, effective, and cost-appropriate treatment for sustainable weight loss.

Scientific References

1. Frias, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Summary of Product Characteristics: Mounjaro 2.5 mg solution for injection. MHRA UK. [accessed 15 August 2026]
3. Wilding, J. P., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. NICE Technology Appraisal Guidance TA875. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.